Omalizumab Liquid
NDC Package 0078-1336-09
Package Information
Omalizumab liquids is omalizumab is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma that is due to year-round allergens. This formulation utilizes a liquid delivery system. Marketed by Novartis Pharmaceuticals Corporation, this product is identified by NDC 0078-1336.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0078 - Novartis Pharmaceuticals Corporation
- 0078-1336 -
- 0078-1336-09 - 2 kg in 1 BOTTLE
- 0078-1336 -
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0078-1336-09 identifies a specific commercial package of 2 kg in 1 bottle of Omalizumab (UNFINISHED drug), a bulk ingredient labeled by Novartis Pharmaceuticals Corporation. This liquid is formulated for use and contains omalizumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novartis Pharmaceuticals Corporation on June 20, 2003. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Omalizumab is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma that is due to year-round allergens. Controlling symptoms of asthma helps you maintain your normal activities and cuts down on time lost from work or school. Omalizumab is also used to treat hives from an unknown cause (chronic idiopathic urticaria-CIU). This medication must be used regularly to be effective. It does not work right away. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, salbutamol) as prescribed.
How is this Novartis Pharmaceuticals Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00078133609. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.